Alcoholic liver disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Alcoholic liver disease remains the main cause of complicated course of liver diseases with high mortality throughout the world. Excessive use of alcohol with harmful health consequences is an extremely urgent problem for Russia. Hepatic cirrhosis makes a significant contribution to the population mortality from diseases of the digestive system. The majority of patients with ALD have a mild alcohol dependency, with rare hangover syndrome, which allows them to drink alcohol for many years. Subclinical course of ALD up to the formation of cirrhosis is very common in such patients. This leads to the inability to provide timely medical care and prevent cirrhosis. The assessment of severity and short-term life prognosis in patients with ALD is based on various prognostic models. The basis of the concepts of ALD pharmacotherapy includes effect on the pathogenetic components of this pathology. L-ornithine L-aspartate is one of the drugs used for pharmacotherapy of ALD of various severity. Treatment with L-ornithine L-aspartate is carried out according to the schemes determined by the course of ALD (alcoholic hepatitis and alcoholic cirrhosis).

Full Text

Restricted Access

About the authors

Tatyana E. Polunina

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: poluntan@mail.iu
MD, Professor

References

  1. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2017;27(6):20-40
  2. Stickel F., Datz C., Hampe J., Bataller R. Pathophysiology and Management of Alcoholic Liver Disease: Update 2016. Gut and Liver. 2017;11(2):173-188.
  3. Yoon Y.-H., Chen C.M. Surveillance Report #105. Liver cirrhosis mortality in the United States: national, state, and regional trends, 2000-2013. 2016 (cited 19 April 2017). Available at https:// pubs.niaaa.nih.gov/publications/surveillance105/ Cirr13.htm.
  4. Louvert A., Peck-Radosavljevic M. Evidence for a role of genetics in alcoholic hepatitis: Data from the STOPAN randomozed controlle of trial. J. Hepatol. 2017;67(1):2-14.
  5. Salameh H., Raff E., Erwin A., et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am. J. Gastroenterol. 2015;110:846-56.
  6. Gao B., Bataller R. Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets. Gastroenterol. 2011;141:1572-85.
  7. Singal A.K., Bataller R., Ahn J. ACG Clinical Guideline: Alcoholic Liver Disease. Am. J. Gastroenterol. Adv. On-line publicat. 16 January 2018.
  8. Полунина Т.Е. Стратегия диагностики и лечения алкогольной болезни печени. Фарматека. 2012;7(240):58- 63.
  9. Маев И.В., Абдурахманов Д.Т., Андреев Д.Н., Дичева Д.Т. Алкогольная болезнь печени: современное состояние проблемы. Терапевтический архив. 2014;4:108-11.
  10. Dunn W., Angulo P., Sanderson S., et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterol. 2006;131: 1057-63.
  11. Maddrey W.C., Boitnott J.K., Bedine M.S., et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterol. 1978;75(2):193-99.
  12. Dunn W., Jamil L.H., Brown L.S., et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatol. 2005;41:353-58.
  13. Forrest E.H., Evans C.D., Stewart S., et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54(8): 1174-79.
  14. Dominguez M., Rincon D., Abraldes J.G., et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J. Gastroenterol. 2008;103:2747-56.
  15. Louvet A., Naveau S., Abdelnour M., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatol. 2007;45:1348-54.
  16. Louvet A., Labreuche J., Artru F., et al. Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis. Gastroenterol. 2015;149:398-406.
  17. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J. Hepatol. 2018;69:154-81.
  18. Соловьева Г.А., Кваченюк Е.Л. Гепа-Мерц влечении алкогольного инеалкогольного стеатогепатита. ЛіЫ У^аіни. 2011;7:64-70.
  19. Stewart C.A., Menon K.V.N., Kamath P.S. Hepatic encephalopathy - diagnosis and management. In: Neurological Therapeutics Principles and Practice. 2nd ed. Vol. 2. Ed. by J.H. Noseworthy. Ch. 119. Abingdon: Informa Healthcare, 2006. P. 1432-40.
  20. Grüngreiff K., Lambert-Baumann J. Efficacy of L-ornithine-L-aspartate granules in the treatment of chronic liver disease. Med Welt. 2001; 52:219-26.
  21. Kit Z.M. Experience of administration of l-ornithine-l-aspartate in the treatment of patients with alcoholic liver disease. N. Armen Med J. 2017;1 1(2):72-76.
  22. Агеева Е.А., Алексеенко С.А. Применение пероральной формы L-орнитин-L-аспартата при гипераммониемии у больных с хроническими заболеваниями и печени на доцирротической стадии. Эффективная фармакотерапия. 2017 16:6-9.
  23. Дворкина Н.В., Холина И.М., Ермолова Т.В. и др. Эффективность применения L-орнитина-L-аспартата у больных стеатогепатитом. Современная гастроэнтерология и гепатология. 2012;1:1-5.
  24. Ильченко Л.Ю., Мельникова Л.И., Журавлева М. В. Experience in the use of ornithine aspartate and probiotic Biofiorum Forte in the treatment of non-severe forms of alcoholic and non-aicoholic fatty liver disease. Архивъ внутренней медицины. 2016;5:45-52.
  25. Jiang Q., Jiang X.H., Zheng M.H., Chen Y.P. L-Ornithine-i-aspartate in the management of hepatic encepha-iopathy: a meta-analysis. J. Gastroenterol Hepatol. 2009;24:9-14.
  26. Буеверов A.O. Патогенетические основы печеночной энцефалопатии: фокус на аммиак. Клинические перспективы гастроэнтерологии гепа -тологии. 2012;6:3-10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies